Abstract: The objective of the study is to assess the prevalence of diabetic retinopathy and determine the correlation of incidence and severity of retinopathy with systemic risk factors in type 2 diabetes mellitus. 500 subjects of both sexes, with the mean age of 55±8 years, with type 2 diabetes mellitus were included in the study. Patients were screened for presence of associated risk factors including duration and control of hyperglycemic status, hypertension, hyperlipidemia, HbA1C, nephropathy, neuropathy and anemia. Ophthalmoscopic examination was performed after pupillary dilatation and staging of diabetic retinopathy is done. 334 out of 500 patients (66.8%) had diabetic retinopathy and the prevalence was higher in elderly above 60 years and those with severe grades of systemic risk factors. Amongst the 1000 eyes studied, 573 were classified as non-proliferative diabetic retinopathy (NPDR) and 33 as proliferative diabetic retinopathy (PDR). Prevalence of mild non-proliferative, moderate non-proliferative, severe non-proliferative, very severe non-proliferative and proliferative diabetic retinopathy were 14%, 41.8%, 30.3%, 8.2% and 5.4% respectively. A significant association was observed between the duration of diabetes and the presence and severity of diabetic retinopathy. Prevalence of anemia, nephropathy, hyperlipidemia and peripheral neuropathy in patients with retinopathy was 42.5%, 12.2%, 75.4% and 9.3% respectively. Diabetic retinopathy and systemic complications run parallel in most patients. Prevalence and severity of diabetic retinopathy was more in patients with longer duration of diabetes and with more systemic complications. Hyperlipidemia is a major marker for retinopathy and these patients need ophthalmic evaluation at the earliest.

Keywords: Diabetic retinopathy, nephropathy, hyperlipidemia, neuropathy, hypertension, systemic complications.

INTRODUCTION:
Diabetes mellitus is a group of metabolic disorders producing hyperglycaemia [1]. The globally estimated number of diabetic patients is around 150 million. This prevalence rate (about 5.4%) is predicted to double by 2025, with most number of cases being expected in China and India [2]. The expected number of diabetic patients is to rise from 171 million in 2000 to 366 million in 2030 [3].

Diabetic retinopathy is found to be the leading cause for acquired blindness and one of the leading causes of visual deficit in the working population of both developed and developing countries [4]. It is the sixth cause of blindness in India and is increasing day by day [4]. Indians are also susceptible to the major complications related to diabetes like coronary artery disease, neuropathy, nephropathy and retinopathy. The important risk factors for the high prevalence of diabetes include high familial aggregation, central obesity, insulin resistance and lifestyle changes due to urbanization [5, 6, 7]. Prevalence of the complications is higher in lower socio-economic groups due to lack of good control of diabetes and hypertension and also due to behavioral factors [7].

The direct and indirect costs involved in the treatment of the chronic disease especially when associated with the vascular complications are enormous. In order to reduce the high morbidity and mortality and also to reduce the cost burden to the patients and to the society, urgent preventive measures must be undertaken [7]. The presence of diabetic retinopathy may indicate the development of systemic complications. Early diagnosis and treatment of diabetic retinopathy is important for prevention of blinding complications. The objectives of the study were to estimate the prevalence of diabetic retinopathy and to determine the correlation of systemic risk factors with retinopathy.

MATERIALS AND METHODS:
This study was approved by the institutional ethics committee. The diabetic patients referred to the
ophthalmology department of the tertiary hospital were included in the study. Type II diabetic patients including new and review cases (diagnosed according to ADA criteria) were recruited into the study for a period of 1 year. Informed consent was obtained from all patients. Clinical data of all patients which included age, sex and duration of diabetes were obtained from the medical records and direct patient interview. Patients of all age groups and both sexes diagnosed with Type II diabetes mellitus were included in the study. Subjects with type 1 diabetes mellitus, secondary diabetes and gestational diabetes were excluded.

Diabetic patients were diagnosed by blood sugar (fasting & post prandial) examination. Blood samples were collected into fluoride oxalate and EDTA bottles for fasting blood glucose (FBG), post prandial blood glucose (PPBG), serum creatinine, blood urea, hematocrit, hemoglobin concentration, HbA1C and lipid profile measurements. Diabetes was diagnosed by participant’s self-report, fasting blood sugar level >126mg/dl, post prandial >155mg/dl and HbA1C values > 6.5%. The condition was confirmed by doing urine, blood sugar examination, and dilated fundus examination according to the criteria of American Academy of Ophthalmology. Diagnosis was established and graded according to Early Treatment of Diabetic Retinopathy Study (ETDRS) criteria. Blood pressure was measured using the sphygmomanometer. The presence of anemia was defined by a hemoglobin level < 13.0 g/dL in men and <12.0 g/dL in women based on definition of World Health Organization (WHO) [18]. Hyperlipidemia was noted when total cholesterol was >200mg/dl. Blood urea levels >45mg/dl and serum creatinine >1.6mg/dl were considered to have nephropathy. Data was collected and analyzed with the help of a proforma for each patient including name, age, sex, duration of diabetes, treatment received and compliance, ocular and systemic factors mentioned above.

RESULTS:

With the above mentioned ranges, the result was calculated and analyzed by using Correlation test and “R” value. Out of 500 patients, 334 were diagnosed with diabetic retinopathy. Hence out of 1000 eyes, 573 were classified as non-proliferative diabetic retinopathy (NPDR) and 33 as proliferative diabetic retinopathy (PDR).

<table>
<thead>
<tr>
<th>DUATION OF DIABETES MELLITUS</th>
<th>GRADE OF DIABETIC RETINOPATHY</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MILD NPDR</td>
<td>MODERATE NPDR</td>
</tr>
<tr>
<td>&lt;1 year</td>
<td>13</td>
<td>59</td>
</tr>
<tr>
<td>1-5 YEARS</td>
<td>59</td>
<td>103</td>
</tr>
<tr>
<td>5-10 YEARS</td>
<td>13</td>
<td>33</td>
</tr>
<tr>
<td>&gt;10YEARS</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>TOTAL</td>
<td>88</td>
<td>206</td>
</tr>
</tbody>
</table>

Table 1: Distribution of patients according to duration of diabetes mellitus and grades of diabetic retinopathy

![Fig 1: Correlation of diabetic retinopathy with duration](image-url)

NPDR – Non Proliferative Diabetic Retinopathy, PDR – Proliferative Diabetic Retinopathy E PDR – Early PDR, HR PDR- High Risk PDR
Fig 2: Distribution of patients based on type of anti-diabetic treatment
OHA – Oral Hypoglycemic Agents

Fig 3: Correlation of diabetic retinopathy with patient compliance

Table 2: Correlation of diabetic retinopathy with glucose levels

<table>
<thead>
<tr>
<th></th>
<th>Mild NPDR $\overline{x} \pm \sigma$</th>
<th>Moderate NPDR $\overline{x} \pm \sigma$</th>
<th>Severe NPDR $\overline{x} \pm \sigma$</th>
<th>PDR $\overline{x} \pm \sigma$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fbs</td>
<td>150.9±59.5</td>
<td>155.11±70.4</td>
<td>168.8±76.1</td>
<td>193.55±71.5</td>
</tr>
<tr>
<td>Ppbs</td>
<td>240.6±99.4</td>
<td>251.4±104.6</td>
<td>270.52±102.1</td>
<td>286.96±88.6</td>
</tr>
<tr>
<td>R value</td>
<td>0.735</td>
<td>0.826</td>
<td>0.782</td>
<td>0.733</td>
</tr>
<tr>
<td>P value</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Fig 4: Correlation between diabetic nephropathy and retinopathy

Table 3: Distribution of patients according to blood urea, serum creatinine and grades of diabetic retinopathy

<table>
<thead>
<tr>
<th></th>
<th>GRADE OF DIABETIC RETINOPATHY</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MILD NPDR</td>
<td>MODERATE NPDR</td>
</tr>
<tr>
<td>Urea (mg/dl)(&gt;45mg/dl)</td>
<td>4</td>
<td>12</td>
</tr>
<tr>
<td>Creatinine (md/dl)</td>
<td>6</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>32</td>
</tr>
<tr>
<td>Both urea &amp; creatinine</td>
<td>2</td>
<td>10</td>
</tr>
</tbody>
</table>
DISCUSSION

Diabetic retinopathy is found to be the leading cause for acquired blindness and one of the leading causes of visual deficit in the working population of both developed and developing countries [4]. The prevalence of diabetic retinopathy was 66.8% in type 2 diabetic patients. This was significantly higher with longer duration of diabetes and severe systemic risk factors. This study provides an improved estimate regarding diabetes mellitus and its long term complications.

Many people were diagnosed as glucose intolerance rather than diabetes mellitus since they did not match the national diabetes data group criteria [8]. Our study provides a comprehensive assessment of the frequency and staging of retinopathy. We found 66.8% of retinopathy among 500 diabetic patients. Similarly Dyck et al.; in their study observed 79% of the IDDM patients and 55% NIDDM patients had retinopathy [9, 10]. The differences obtained may be due to use of different criteria for diabetes mellitus, a different geographic location or failure to detect all diabetic cases in the population. It is commonly inferred that the prevalence of diabetes mellitus and its complications is greatly underestimated because of the many undetected patients in the community [4]. Our data, based on a
patient population that is almost completely surveyed for hyperglycemia, does not support such an underestimate.

Percentages of mild non-proliferative, moderate non-proliferative, severe non-proliferative, very severe non-proliferative and proliferative diabetic retinopathy were 14%, 41.8%, 30.3%, 8.2%, 5.4% respectively. This was also studied in the Rochester diabetic neuropathy study where the percentages of early non-proliferative, late non-proliferative, proliferative type were 16%, 24%, 3% respectively [9, 10]. Klein et al found prevalence values similar to those found in this study [11, 12, 13].

Our estimate of the frequency of nephropathy, on the other hand, is suboptimal since we did not systematically assess 24 hour urine albumin levels. Diabetic nephropathy, an important complication of long standing diabetes mellitus, has been extensively studied [14, 15].

The incidence of anemia in our study (42.5%) may be due to smaller sample size, which was largely those who had poorly controlled diabetes, who may be susceptible to impaired erythropoietin production due to diabetic neuropathy. In contrast, prevalence of 20% has been reported in diabetes with renal insufficiency [16, 17].

A reason for the difference is that we used the national diabetes data group criteria for the diagnosis of diabetes mellitus, unlike other studies [4]. Many people were diagnosed as glucose intolerance rather than diabetes mellitus since they did not match the national diabetes data group criteria [8]. We observed a strong association between the duration of diabetes and the onset of retinopathy. 56.3% acquired retinopathy in the first 5 years after diagnosis.

Patients with less treatment compliance had a higher rate of retinopathy (75.4%). On comparison with other systemic risk factors it was found to have a higher correlation with the progression of retinopathy.

Hyperlipidemia is an important risk factor for development of retinopathy in diabetes. Our study shows a prevalence of 75.4% which was also observed in A Ramachandran et al.; in their study which showed a prevalence of 57% in males and 5% in females [18]. This difference may be due to lesser number of patients recruited in our study.

It is a proven fact that diabetic autonomic neuropathy is a complication of poor glycemic control. It is established that diabetic polyneuropathies can cause a high morbidity and even death. Most diabetic patients develop these complications in due course of time, and amongst all neuropathies, diabetic varieties are among the most frequent and disabling [19, 20]. As noted by Lund beck, Melton and Dyck, the data underlying such assumptions are of poor quality. We assume that the rate of problematic cases of neuropathy might be somewhat higher if premature death had not occurred among Rochester diabetic patients. The prevalence of peripheral neuropathy among diabetics was 9.3% as compared to 6% of NIDDM in Rochester study [21, 22].

Other factors which have been reported to increase the risk of anemia include systemic inflammation; damage to renal architecture produced by chronic hyperglycemia and formation of advanced glycation end products and depressed androgen levels induced by diabetes [18, 23, 24]. It is speculated that these conditions may be aggravated in poorly controlled diabetes than in controlled diabetes.

**CONCLUSION:**

The study shows that patients with longer duration of diabetes, uncontrolled hyperglycemia and those with associated systemic manifestations have a higher prevalence and severity of diabetic retinopathy. Diabetic retinopathy and systemic complications appear to be strongly associated. Hyperlipidemia is a major marker for retinopathy and these patients need ophthalmic evaluation at the earliest. Prevalence and severity of diabetic retinopathy was more with the increasing duration of diabetes and with systemic complications like nephropathy and neuropathy. Further studies need to be undertaken to strengthen the etiological relationship. However, it should be emphasized that examination of systemic risk factors should be an integral part of the assessment of diabetic eye disease.

**REFERENCES:**

6. Mohan V, Sharp PS, Cloke HR, Burdin JM, Schume B, Kohler EM; Serum immuno reactive insulin responses to a glucose load in Asian Indian


